Search

Your search keyword '"Raquel Salvador Laureano"' showing total 3 results
Start Over Author "Raquel Salvador Laureano" Language english
3 results on '"Raquel Salvador Laureano"'

1. IL-1R signaling drives enteric glia-macrophage interactions in colorectal cancer

Author

Lies van Baarle, Veronica De Simone, Linda Schneider, Sneha Santhosh, Saeed Abdurahiman, Francesca Biscu, Reiner Schneider, Lisa Zanoletti, Renata Siqueira de Mello, Sara Verbandt, Zedong Hu, Michelle Stakenborg, Bo-Jun Ke, Nathalie Stakenborg, Raquel Salvador Laureano, Balbina García-Reyes, Jonas Henn, Marieta Toma, Maxime Vanmechelen, Guy Boeckxstaens, Frederik De Smet, Abhishek D. Garg, Sales Ibiza, Sabine Tejpar, Sven Wehner, and Gianluca Matteoli

Subjects
Science
Abstract

Abstract Enteric glia have been recently recognized as key components of the colonic tumor microenvironment indicating their potential role in colorectal cancer pathogenesis. Although enteric glia modulate immune responses in other intestinal diseases, their interaction with the colorectal cancer immune cell compartment remains unclear. Through a combination of single-cell and bulk RNA-sequencing, both in murine models and patients, here we find that enteric glia acquire an immunomodulatory phenotype by bi-directional communication with tumor-infiltrating monocytes. The latter direct a reactive enteric glial cell phenotypic and functional switch via glial IL-1R signaling. In turn, tumor glia promote monocyte differentiation towards pro-tumorigenic SPP1+ tumor-associated macrophages by IL-6 release. Enteric glia cell abundancy correlates with worse disease outcomes in preclinical models and colorectal cancer patients. Thereby, our study reveals a neuroimmune interaction between enteric glia and tumor-associated macrophages in the colorectal tumor microenvironment, providing insights into colorectal cancer pathogenesis.

Published
2024
Full Text
View/download PDF

2. A Mycobacterium tuberculosis-specific subunit vaccine that provides synergistic immunity upon co-administration with Bacillus Calmette-Guérin

Author

Joshua S. Woodworth, Helena Strand Clemmensen, Hannah Battey, Karin Dijkman, Thomas Lindenstrøm, Raquel Salvador Laureano, Randy Taplitz, Jeffrey Morgan, Claus Aagaard, Ida Rosenkrands, Cecilia S. Lindestam Arlehamn, Peter Andersen, and Rasmus Mortensen

Subjects
Science
Abstract

Tuberculosis (TB) subunit vaccines have been investigated as boosters for BCG-induced immunity. Here, the authors design a TB subunit vaccine that doesn't share antigens with BCG and show that co-administration of the two vaccines broadens the T cell response to TB and increases protection.

Published
2021
Full Text
View/download PDF

3. A Mycobacterium tuberculosis-specific subunit vaccine that provides synergistic immunity upon co-administration with Bacillus Calmette-Guérin

Author

Peter Andersen, Karin Dijkman, Cecilia S. Lindestam Arlehamn, Helena Strand Clemmensen, Jeffrey Morgan, Joshua S. Woodworth, Claus Aagaard, Randy Taplitz, Ida Rosenkrands, Rasmus Mortensen, Thomas Lindenstrøm, Raquel Salvador Laureano, and Hannah Battey

Subjects
Protein vaccines, Tuberculosis, T cell, Protein subunit, Science, General Physics and Astronomy, complex mixtures, Article, General Biochemistry, Genetics and Molecular Biology, Mycobacterium tuberculosis, Mice, Immunogenicity, Vaccine, SDG 3 - Good Health and Well-being, Antigen, In vivo, Immunity, medicine, Animals, Humans, Tuberculosis Vaccines, Antigens, Bacterial, Multidisciplinary, biology, Vaccination, General Chemistry, Th1 Cells, biology.organism_classification, medicine.disease, Mycobacterium bovis, Virology, medicine.anatomical_structure, Vaccines, Subunit, BCG Vaccine, Th17 Cells
Abstract

Given the encouraging clinical results of both candidate subunit vaccines and revaccination with Bacillus Calmette-Guérin (BCG) against tuberculosis (TB), there is support for combining BCG and subunit vaccination for increased efficacy. BCG and Mycobacterium tuberculosis (Mtb) share ~98% of their genome and current subunit vaccines are almost exclusively designed as BCG boosters. The goal of this study is to design a TB subunit vaccine composed of antigens not shared with BCG and explore the advantages of this design in a BCG + subunit co-administration vaccine strategy. Eight protective antigens are selected to create an Mtb-specific subunit vaccine, named H107. Whereas traditional vaccines containing BCG-shared antigens exhibit in vivo cross-reactivity to BCG, H107 shows no cross-reactivity and does not inhibit BCG colonization. Instead, co-administering H107 with BCG leads to increased adaptive responses against both H107 and BCG. Importantly, rather than expanding BCG-primed T cells, H107 broadens the overall vaccine repertoire with new T cell clones and introduces ‘adjuvant-imprinted’ qualities including Th17 responses and less-differentiated Th1 cells. Collectively, these features of H107 are associated with a substantial increase in long-term protection., Tuberculosis (TB) subunit vaccines have been investigated as boosters for BCG-induced immunity. Here, the authors design a TB subunit vaccine that doesn't share antigens with BCG and show that co-administration of the two vaccines broadens the T cell response to TB and increases protection.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results